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A series of 5-aryl-1-alkylimidazole derivatives was synthesized using the van Leusen multicomponent 
reaction. The chemotype is the first example of low-basicity scaffolds exhibiting high affinity for 5-HT7 
receptor together with agonist function. The chosen lead compounds 3-(1-ethyl-1H-imidazol-5-yl)-5-
iodo-1H-indole (AGH-107, 1o, Ki 5-HT7 = 6 nM, EC50 = 19 nM, 176-fold selectivity over 5-HT1AR) and 1e 
(5-methoxy analogue, Ki 5-HT7 = 30 nM, EC50 = 60 nM) exhibited high selectivity over related CNS targets, 
high metabolic stability and low toxicity in HEK-293 and HepG2 cell cultures. A rapid absorption to the 
blood, high blood-brain barrier permeation and a very high peak concentration in the brain (Cmax = 2723 
ng/g) were found for 1o after i.p. (5 mg/kg) administration in mice. The compound was found active 
in novel object recognition test in mice, at 0.5, 1 and 5 mg/kg. Docking to 5-HT7R homology models 
indicated a plausible binding mode which explain the unusually high selectivity over the related CNS 
targets. Halogen bond formation between the most potent derivatives and the receptor is consistent 
with both the docking results and SAR. 5-Chlorine, bromine and iodine substitution resulted in a 13, 27 
and 89-fold increase in binding affinities, respectively, and in enhanced 5-HT1AR selectivity.
Within the serotonergic system, 5-HT7, the last identified serotonin receptor, is one of the most valuable drug 
targets1. Discovered independently by three laboratories in 1993 2–4, 5-HT7R was thought to function by being 
coupled to Gs to stimulate intracellular production of cAMP, but it was later found to also be coupled to G12 which 
is an alternative signal transduction pathway5. 5-HT7R is expressed in the central nervous system (thalamus, 
hypothalamus, hippocampus and cortex) as well as peripherally (pancreas, spleen, coronary artery, ileum and 
intestine)3–6. Experiments using animal models have shown that the receptor is involved in many physiologi-
cal processes, i.e. the regulation of body temperature7, smooth muscle relaxation of cerebral arteries8, circadian 
rhythm, learning and memory9–13, as well as pathophysiological processes such as mood disorders, anxiety14, 
inflammatory processes in the CNS15, schizophrenia16 and pain17, 18. 5-HT7R antagonists have been proposed 
as potential drugs targeting depression19, 20. There have been less conclusive reports on potential anxiolytic21, 22, 
analgesic17 and antipsychotic properties of the receptor ligands23, 24. It was established that 5-HT7R blockade can 
induce promnesic effects indicating the possibility of developing atypical procognitive antidepressants25.
There are several 5-HT7R agonists available to serve as molecular probes. These include small, low-weight mol-
ecules, e.g. AS-1926, RA-77, 5-carboxyamidotryptamine (5-CT), 5-methoxytryptamine, 8-OH-DPAT27, and lyser-
gic acid derivatives28 and long-chain diphenylpiperazines (LP-12, LP-44, LP-211) developed by Leopoldo et al.29–31. 
None of these compounds qualify as perfect radioligand candidates, mainly due to their poor selectivity. 5-HT7R 
agonists often bind to 5-HT1AR and 5-HT5AR32. Some promising 5-HT7R molecular probes suffer from poor 
metabolic stability33. In the case of larger molecules, membrane penetration may be an issue as it is considerably 
harder to find an optimal mass-lipophilicity ratio. Animal models suggest several possible indications of 5-HT7R 
agonists as therapeutics. The stimulation of 5-HT7R in adolescent rats by LP-211 causes plastic rearrangements 
within the forebrain networks, accounting for long-lasting behavioural changes in adulthood34. The activation of 
5-HT7R was found to be beneficial in mouse models of Rett syndrome35 and fragile X syndrome36. Compound 
AS-19, which was the first selective agonist of the 5-HT7R, as well as LP-12, LP-44, LP-211 and E-55888 have 
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been used in numerous in vivo experiments which led to the characterization of the receptor. It was found, that 
5-HT7 agonists can enhance long-term memory formation. In animal models of pain, AS-19, LP-44 and LP-211 
were found antinociceptive. The antinociceptive properties of morphine can be dramatically enhanced by the 
co-administration of the E-55888, while the compound does not produce any analgesic effect on its own37.
Non-basic aminergic GPCR ligands have recently emerged as pharmacological rule breakers. Despite lack-
ing the capability of forming a salt bridge (strong, charge assisted hydrogen bond) with Asp3.32 such chemical 
entities have been shown to bind to 5-HT2AR38 and later to 5-HT6 and 5-HT1B receptors with nanomolar and 
subnanomolar potencies39, 40. Interestingly, there have been no published examples of low-basicity ligands of the 
5-HT7 receptor41. A hypothesis that an aromatic basic moiety can successfully serve as the aminergic fragment of 
a serotonin receptor ligand was not yet tested. Till date there were numerous basic scaffolds (piperazine, piperi-
dine, pyrrolidine, polycyclic amines, alkylamines) incorporated into serotonin receptor ligands. The imidazole 
fragment, which is a privileged structure commonly used in medicinal chemistry, has not been tested as a basic 
fragment in the aminergic GPCR field and was hardly used as a part of serotonin receptor ligands42.
Our initial hypothesis was that multicomponent reaction (MCR) protocols can be successfully applied to the 
field of GPCR ligand synthesis. We believed that the close serotonin analogues 1a (AGH-38) and 1b (AGH-39) 
(Figs 1 and 2), which can be concisely prepared via van Leusen tosylmethylisocyanide (TosMIC) imidazole syn-
thesis43, 44, would exhibit activity at some serotonin receptors.
Owing to the click-chemistry properties of van Leusen imidazole synthesis, different 1-substituted, 5-arylated 
imidazoles were conveniently prepared and evaluated. The MCR protocol enabled the systematic SAR exploration 
by first optimizing the core containing carbonyl component, then optimizing the amine component for the most 
active entities. Over the course of the project it became clear that potent and selective, non-basic 5-HT7R ligands 
can arise via the SAR exploration of the close chemical space of arylimidazoles.
Results and Discussion
Chemistry. Compounds 1a–1q, 1s–1w, 1y–1za, 2b–2f and 3a–3d (Fig. 2) were synthesized using a concise 
multicomponent protocol (Fig. 1). The van Leusen reaction proceeds via the stepwise cycloaddition of TosMIC 
to a polarized double bond of the preformed imine. The elimination of p-toluenesulfonic acid from the cyclic 
intermediate affords imidazole. Aromatic aldehydes were combined with appropriate amines in methanol. When 
the imine formation equilibrium was achieved, TosMIC and potassium carbonate were added to yield the desired 
products. Most of the indole-3-carboxaldehydes used were synthesized by the Vilsmeier-Haack formylation of the 
appropriate indoles. Derivatives 1r and 1x were synthesized by reductive debenzylation of 1y and 1 s, respectively. 
Compound 1za was synthesized from 1p by the controlled hydrolysis of the cyano group in basic conditions.
Pharmacology. All the synthesized compounds were tested in a radioligand binding assays to determine 
their affinity for five receptors: 5-HT1A, 5-HT2A, 5-HT6, 5-HT7 and D2. The assays were performed via the dis-
placement of the respective radioligands from cloned human receptors, all stably expressed in HEK293 cells 
(except for 5-HT2A which was expressed in CHO cells): [3H]-8-OH-DPAT for 5-HT1AR, [3H]-ketanserin for 
5-HT2AR, [3H]-LSD for 5-HT6R, [3H]-5-CT for 5-HT7R and [3H]-raclopride for D2R. Ligands with a high affinity 
for the 5-HT7 receptor were selected for a functional assay (as hydrochloride salts). The experiment was per-
formed in HEK293 cells overexpressing 5-HT7R, and the ability of tested compounds to increase cAMP pro-
duction was measured. The cAMP concentration was measured using TR-FRET and a cAMP specific antibody. 
Lead compounds 1e (AGH-44) and 1o (AGH-107) were screened toward several CNS targets (Eurofins Cerep, Le 
Bois l’Eveque, 86600 Celle L’Ev-escault, France, www.cerep.fr): α1, α2C, CB1, H1, D3, 5-HT1B, 5-HT2B and 5-HT5A. 
The intrinsic clearance of 1e and 1o were determined using human liver microsomes according to Obach et al.45 
(see Supporting Information for detailed results). The HEK-293 and HepG2 cell lines viabilities were tested after 
72 h of incubation with tested compounds. Doxorubicin (DX), and carbonyl cyanide 3-chlorophenylhydrazone 
(CCCP) were used as internal standards (see Supporting Information). The pharmacokinetics of compound 1o 
was tested on CD-1 mice after intraperitoneal injection at 5 mg/kg dose (see Supporting Information). The com-
pound 1o was administered at 0.5, 1 and 5 mg/kg to investigate the ability of the compound to reverse MK-801 
Figure 1. Van Leusen imidazole synthesis.
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Figure 2. Structure, binding data and Central Nervous System Multiparameter Optimization score (CNS 
MPO) of compounds 1a–1za, 2a–2f and 3a–3d.
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induced impairment in novel object recognition test. The experiment was conducted on Albino Swiss mice (see 
Supporting Information).
Structure-Activity Relationship. After acquiring highly encouraging initial results for compounds 1a and 
1b (Ki 5-HT7 = 385 nM and 50 nM, respectively, selectivity over 5-HT1AR > 11-fold, Fig. 2) a literature search made 
us realize that an arylimidazole 5-HT7R ligand was recently described, although no SAR studies were reported46. 
The compound, 5-(4-([11C]methoxyphenyl)-1-methyl-4-nitro-1H-imidazole, 2a, has been developed as a PET 
radioligand. The high and rapid uptake of 2a to the rat brain after injection was reported which would suggest at 
least decent ADME properties. The finding further encouraged us to explore the series, so 2a was resynthesized to 
serve as a reference compound. However, we were not able to reproduce the results presented by Tiwari et al.46. In 
our radioligand displacement binding assays compound 2a did not bind to 5-HT7R and 5-HT1AR (binding curves 
of compound 2a can be found in Supporting Information). Moreover, a very close analogue of 2a (the only struc-
tural difference being the lack of the nitro group) – 2b – was also found to be completely inactive. A compound 
based on the 2,5-dimethoxy-4-iodophenyl core, which is a scaffold common to many 5-HT2R ligands47, 48, 2f 
was expected to bind to 5-HT2AR, but this assumption was not validated. Compounds synthesized from unsub-
stituted and differently methoxy-substituted benzaldehydes (entries 2c–2e) were also not active. Compounds 
3a–3d were synthesized to answer the question of whether methylimidazoles coupled to different aromatic cores 
(3-pyrrole, 2-indole, 5-indole, or 6-indole) could show any 5-HT7R activity. This group of compounds did not 
bind to 5-HT7R at all, even 3a which is a close, simplified analogue of 1a did not possess any activity. It was thus 
evident that indole-3-imidazole (the core structure of series 1) is the molecular scaffold of choice.
The role of the indole nitrogen atom in the binding of the active compounds to 5-HT7R was determined 
by the synthesis of two derivatives. Entry 1c (Ki 5-HT7 = 5623 nM) which is a methylated analogue of 1a, and 
1d (Ki 5-HT7 > 10000 nM) which is a methylated counterpart of 1b clearly showed that the unsubstituted pyrrole 
fragment plays an important role in receptor binding. Homologues 1b, and 1e–1 g and compounds 1 h, and 
1i were synthesized to optimize the length and shape of the amine component. Apparently, the ethyl substi-
tuted derivative exhibited optimal binding affinity (1e, Ki 5-HT7 = 30 nM). Interestingly, 1 h (R1 = cyclopropyl) and 
1 s (R1 = benzyl) were found to be non-active which would suggest a very narrow space in the binding pocket 
reserved for an alkyl fragment. The modification of the indole containing component resulted in compounds 
1j–1 v. Forbidden positions 2-, 6-, and 7- (R7, R5, and R6) can be clearly observed in entries 1k, 1 u, and 1 v, 
respectively. Compound 1t exhibited moderate activity toward 5-HT7R (Ki = 122 nM) indicating that appropri-
ate substituents are acceptable at the fourth position of the indole nucleus. Although 1j and 1k (4-bromo- and 
6-bromoindole cores, respectively) were found to possess low affinity for 5-HT7R, 1n (5-bromo) was a hit com-
pound with Ki = 20 nM. Successively, a series of 5-substituted indole-containing derivatives were synthesized. 
The activity of compounds 1l–1q and 1w showed a very probable involvement of halogen bonding in the binding 
of the most active derivatives 1m–1o. 5-HT7R affinities of methyl and fluoro derivatives 1q and 1 l (44 nM and 
302 nM, respectively) were considerably lower than for the halogen series (42 nM, 20 nM, and 6 nM for Cl, Br and 
I, respectively), indicating the hydrophobicity to be of secondary importance. Compound 1o (5-iodo) became 
the lead in the series exhibiting Ki = 6 nM at the human 5-HT7 receptor, and 176-fold selectivity over 5-HT1AR. A 
very close serotonin analogue 1r bound to 5-HT7R with Ki = 39 nM, whereas an analogue of 5-CT, 1za displayed 
Ki = 5 nM.
In vitro pharmacology. Functional assay results for the chosen compounds are shown in Table 1. 
Compounds 1b, 1e, 1m, 1n, 1o, 1q and 1r acted as full agonists at the human 5-HT7 receptor. The strongest ago-
nist function was observed for 1o (5-iodo) and 1r (5-hydroxy).
The receptor profile of the tested compounds shows high selectivity over the tested CNS targets. All com-
pounds from chemotype 1 showed Ki > 1000 nM at the 5-HT2A, 5-HT6 and D2 receptors. 1e and 1o were found to 
be selective toward a set of CNS targets (Table 2). Within the extended receptor panel tested, 1e and 1o showed 
affinity only for 5-HT2B (% of inhibition at 1 µM = 93 and 87, respectively), but at a 10 nM concentration, the 
level of receptor binding was very low (6 and 7%, respectively). Additionally, compounds 1e and 1o showed very 
promising metabolic stability with metabolic clearance 3.69 and 6.3 ml/min/kg, respectively.
The cytotoxicity of the compounds 1e and 1o was tested by checking the viability of HEK-293 and HepG2 cells 
after incubation with different concentrations of the compounds in the medium. 1o was found toxic for the cells 
only in the highest concentration (100 μM), while with 1e the cells remained viable in all tested concentrations 
(Fig. 3).
Compound ID R1 R4 Ki 5-HT7REC50 [nM] CYP3A4 IC50 [μM] Clinta [ml/min/kg]
1b Me OMe 55 150 — —
1e Et OMe 30 60 0.24 3.69
1m Et Cl 42 149 — —
1n Et Br 20 154 — —
1o Et I 6 19 0.17 6.3
1q Et Me 44 45 — —
1r Et OH 39 22 — —
Table 1. Results of functional activity for 5-HT7R, CYP3A4 inhibition assay and metabolic stability for the 
selected compounds. aMetabolic clearance (human liver microsomes).
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Preliminary pharmacokinetics and behavioural study. The pharmacokinetic analysis performed by 
a non-compartmental approach has shown a rapid absorption of 1o after i.p. administration (tmax = 15 min) with 
maximum plasma concentration of 749 ng/mL (~2.2 μM) (Fig. 4). Half of the compound was eliminated from 
the body within 90 min but brain concentrations of compound 1o decreased slowly with t0.5 = 130 min. Large 
volume of distribution (Vd/F = 46.6 L/kg) indicated the penetration of 1o into the peripheral compartments. The 
compound 1o was measurable to the last sampling time (6 h) both in plasma and brain. The compound pene-
trated the blood-brain barrier after i.p. administration and peaked in the brain and plasma at the same time but 
the maximum concentration in the brain was higher (Cmax = 2723 ng/g, approx. 8 μM). The mean residence time 
(MRT) for compound 1o in brain was longer than in plasma and equalled 60 min and 27 min, respectively. The 
brain to plasma ratio was high and equal 6.34. The detailed description of the pharmacokinetic experiment can be 
found in the Supporting Information. In a recent paper by Leopoldo et al.31 a disposition study for 5-HT7R ago-
nists LP-44 and LP-211 after i.p. administration at a dose of 10 mg/kg in mice was reported. Despite 1o reached 
the Cmax in approx. 15 min, which is roughly the same for both LP compounds, the maximum concentrations of 
LP-44 and LP-211 in the brain were found several-fold lower than for 1o, despite the dose used was twice as high 
as that of 1o. The LP compounds were measurable in plasma for a very short time compared to over 6 hours for 1o 
which can be attributed to their very low metabolic stability. The blood/plasma ratio for 1o was three-fold higher 
compared to LP-44 and 9 times higher than for LP-211.
Considering the PK study and suitable brain penetration we concluded that 1o has desirable pharmacoki-
netic profile to be characterized as a compound of choice to study the in vivo pharmacology. The compound 
dose-dependently reversed MK-801-induced disruption in novel object recognition (NOR) in mice (Fig. 5). 
This finding is in line with the results obtained earlier for 5-CT49. MK-801-induced disruption of novel object 
recognition in rodents reflects impairment of working memory, regarded as one of the cognitive symptoms of 
schizophrenia.
Molecular modelling. For all compounds in the series, Multiparameter Optimization (MPO) based on six 
factors (molecular weight, number of hydrogen bond donors, calculated: basic pKa, topological polar surface area, 
Compound
Concentra- 
tion [M]
% Inhibition of control bindinga
α1 α2C CB1 D3 H1 5-HT1B 5-HT2B 5-HT5A
1e
10−6 5 9 8 8 6 24 93 9
10−8 — — — — — — 6 —
1o
10−6 — — — — — 40 87 7
10−8 — — — — — — 7 —
Table 2. Anti-target profiles of selected compounds 1e and 1o. aExperiments performed at Eurofins Cerep.
Figure 3. The HEK-293 and HepG2 cell lines viability in the presence of 1e and 1o after 72 h of incubation.
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logP, logD) was performed. MPO parameter which was calculated according to Wager et al.50 was found to lie 
between 4–6 for most of the compounds in the series (Fig. 2).
A very promising group of 5-HT7 receptor agonists has been developed. To make the search for highly active 
molecules more rational and explain the unusually high selectivity, a binding mode model had to be explored. 
The proposed binding mode was based on the analysis of the mutual spatial arrangement of particular ligands at 
the 5-HT7 receptor homology models. The final analysis and visualizations were performed using a model built 
on a 5-HT1BR (4IAR, complex with agonist, ergotamine) template, because it showed the most coherent binding 
mode, combined with low binding free energies (see Experimental Section). The observed structure-activity rela-
tionships were in agreement with the docking results. Quantum chemical calculations of pKa for 1w (performed 
in Jaguar using DFT functional B3PW91 and the cc-pVTZ basis set) showed an imidazole fragment pKa = 6.9, 
indicating that the molecules at physiological pH = 7.4 occur in protonated (33%) as well as deprotonated (67%) 
forms. Two protonation states for each ligand were considered in docking study. The virtual ligand-receptor com-
plexes of the protonated states did not follow the observed SAR, in addition, a more coherent binding mode was 
found for the unprotonated forms of the compounds. Thus in discussion and visualizations only deprotonated 
ligand-receptor complexes were used. The indole nucleus in all the docked ligands formed a hydrogen bond 
with Asp3.32 and aromatic interactions (CH-π or π-π stacking) with the Phe6.51 or Phe6.52 residues (Fig. 6A), 
whereas the imidazole ring was frequently hydrogen bonded to Arg6.58. It should be emphasized, that among all 
targets tested in vitro, the arginine in position 6.58 is a unique feature of 5-HT7R (Table 3)51, which could explain 
the high selectivity of the discussed compounds.
The substitution of hydrogen to a halogen atom in position 5 of the indole ring, proportionally increased the 
5-HT7R affinity to the size of the halogen atom. The analysis of binding modes, showed that a significant contribu-
tion to the binding can be attributed to the halogen bond created between the ligand and carbonyl oxygen of one 
or several amino acids of transmembrane helix 5 (TMH5). The geometric parameters for the 5-iodine derivative 
showed the significant contribution of Ser5.42 (d(I···O) = 3.1 Å, sigma hole angle (C–I···O) = 155°) and Thr5.39 
(d(I···O) = 4.4 Å, sigma hole angle (C-I···O) = 171°) (Fig. 6A). Additionally, the order of the binding free energy 
changes (after chlorine, bromine and iodine substitution ∆∆G was −6.6, −7.2 and −10.1 kcal/mol, respectively) 
and the interaction sphere plotted onto the relevant backbone carbonyl oxygen (all X···O=C interactions were 
within the energetically favourable areas of the sphere, Fig. 6A and B) confirmed the role of halogen bonding 
Figure 4. Concentration – time profiles for 1o in plasma and brain after intraperitoneal administration to mice 
at a dose of 5 mg/kg (linear plots). Concentrations of 1o in plasma and brain are expressed as ng/mL and ng/g, 
respectively.
Figure 5. Reversal of MK-801 induced disruption in novel object recognition. Statistically significant effect was 
found at 1 mg/kg and 5 mg/kg doses.
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in the formation of the L-R complexes. The interaction spheres plotted onto the backbone carbonyl oxygen of 
Ser5.42 were also used to explain the decreased activity upon shifting the bromine atom from position 5 to 4 or 
6 in the indole ring (Fig. 6B). The obtained interaction sphere showed that 5-Br derivative (d(Br···O) = 3.2 Å, 
sigma hole angle (C-Br···O) = 159°) lies within the energetically favourable areas of the sphere, while the 4- and 
6-Br derivatives bromine atoms were pointed outside the sphere, ruling out the formation of halogen bond. This 
observation is consistent with calculated binding free energy values: only 5-bromo derivative 1n showed a gain 
in the binding energy (ΔΔG = −7.6 kcal/mol), compared to the 4-bromo and 6-bromo analogues (ΔΔG = +0.9 
and +1.8 kcal/mol, respectively).
The significance of the hydrogen bond formed between the indole NH group and the Asp3.32 side chain 
can be observed by comparing compounds 1e and 1d (Figs 2 and 6D). The substitution of hydrogen with a 
Figure 6. Representative complexes (top scores based on ΔG) of selected ligands with the 5-HT7 receptor 
model. Amino acids that were selected as crucial for the binding of the presented compounds are shown as 
sticks. The ∆∆G [kcal/mol] value shows the difference between the ∆G of complexes of a particular compound 
(1d, 1 f, 1j, 1k, 1n, 1r, 1t) and an unsubstituted analogue 1w (green in Fig. A). In all cases except 1d (R2 = Me, 
yellow in Fig. D), the ∆∆G values correspond to the binding affinity. (A) – halogen bond formation between 
the iodine atom of 1o and the receptor. (B) – 1j (R5 = Br) and 1k (R3 = Br) which do not pass geometrical 
parameters needed for halogen bond formation and 1n halogen bonded to the receptor. (C) – differences in 
binding modes of compounds 1e (R4 = OMe), 1r (R4 = OH) and 1t (R3 = OMe), the lack of interaction of 1t 
with Ser5.42 is compensated by the formation of additional hydrogen bond with Arg6.58. (D) – the inability of 
1d (R2 = Me) to interact with Asp3.32.
Target 5-HT1AR 5-HT2AR 5-HT2BR 5-HT6R 5-HT7R D2R
6.57 residue Val Met Thr Val Ala Leu
6.58 residue Leu Ala Leu Gln Arg Asn
6.59 residue — Val Val Ala — Ile
Table 3. Amino acid residue at 6.57, 6.58 and 6.59 positions in relevant targets.
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−CH3 group resulted in an approximately 580-fold decrease in binding affinity because no hydrogen bond can be 
formed with Asp3.32. The calculated ΔΔG for the methylated derivative (1d) showed the stabilization of the L-R 
complex which is in sharp contrast with the experimental Ki value (>10000 nM).
Because the discussed compounds are structurally very similar to the class of tryptamines that are known to 
be promiscuous serotonergic agents, representative tryptamine derivatives were purchased and their binding 
affinities for 5-HT7, 5-HT1A, 5-HT2A, 5-HT6 and D2 receptors were determined (Fig. 7).
It is clear that tryptamines (tryptamine as an analogue for 1a; 5-methoxytryptamine for 1b, 1e; 
5-chlorotryptamine for 1m, and 5-methyltryptamine for 1q) exhibit multi-receptor profiles, i.e. a high affinity 
for 5-HT7, 5-HT1A, 5-HT2A, and 5-HT6 receptors. The introduction of halogen at the 5th position of indole in 
tryptamines resulted in an enhancement of the affinity for 5-HT7R, but not nearly as much as the introduction 
of a methoxy group (introduction of the chlorine and methoxy groups had very similar impacts on the binding 
affinity of the title imidazoles). The methylation of the indole NH group in tryptamines resulted in a dramatic 
drop in potency for all four tested serotonin receptors. It was rather unusual that the tryptamines exhibited very 
similar 5-HT7R SARs while exhibiting distinctive multi-receptor profiles. The proposed binding mode for the 
imidazole compounds was compared with several tryptamines, which were docked to the best 5-HT7R homology 
models using the same procedure (Fig. 8). The binding mode of the tryptamine derivatives was similar to the 
findings of Vermeulen et al.52 and was different from the one found for the title compounds. The tryptamines 
formed a salt bridge (charge assisted hydrogen bond) between the protonated amine moiety and Asp3.32, but did 
not interact with Arg6.58. Vermeulen suggested Thr5.43 to be the anchoring point of 5th position substituent of 
tryptamines. The sharp drop in potencies of 1-methylated tryptamines at 5-HT7R contributes to the significance 
of indole NH – Thr3.37 interaction (Fig. 8A–D) Despite different binding modes (Fig. 8D), the 5-HT7R SARs of 
tryptamines and imidazoles are very similar due to involvement of indole 5-substitutent interaction with Ser5.42 
(or Thr5.39) in both series (compare Figs 6C and 8B). Ser5.42 can act as a donor/acceptor of hydrogen bonding 
through the side chain hydroxyl group. The docking results of the imidazole derivatives substituted in position 
5 of the indole by –OCH3 and –OH (1 f (AGH-87) and 1r, Fig. 6C) indicated the formation of a hydrogen bond 
between the hydroxyl group of Ser5.42 and the oxygen atom of substituents. Interestingly, shifting the –OCH3 
group from position 5 to 4, resulted in only a slight decrease in activity, which can be linked to creation of a 
hydrogen bond with Arg6.58 (Fig. 6C).
Apparently, it is possible to synthesize heterocyclic analogues of tryptamines that maintain high affinity and 
agonist function at 5-HT7R. Modelling studies revealed that the incorporation of an amine moiety into an imida-
zole ring resulted in a distinctive binding mode. The difference may be attributed partially to the lower basicity of 
imidazoles versus tryptamines. An interaction with Arg6.58, which is a residue unique for 5-HT7R may underlay 
the observed dramatic effect on the selectivity.
Possible application as a PET radioligand. 5-HT7 receptor is yet to be PET imaged in humans53. No suit-
able 5-HT7R agonist radioligand candidates were reported till date54, 55. Serotonin receptors exist in high and low 
agonist affinity states. The antagonist ligands bind to the high affinity (HA) and low affinity (LA) conformations 
with similar affinity, whereas agonist ligands bind preferentially to the HA state of the receptor, which is coupled 
to G-protein and therefore agonist binding provides a more meaningful functional measure of the serotonin 
receptors activity. Although antagonist PET tracers can measure the total receptor binding, they cannot detect 
changes in the high affinity receptor binding in disease states. Antagonist binding is insensitive to the changes in 
the intra-synaptic 5-HT concentration and antagonist PET tracers are less sensitive for measuring agonist recep-
tor occupancy in clinical studies to guide new drug development in dose-finding56.
Because of rapid penetration to the brain and quick elimination from the CNS, 1o showed desirable properties 
as perspective PET radiotracer. Therefore, a potential synthetic pathway leading to the 11C-labeled version of one 
of the lead compounds (1e) starting with commercially available substrates with only two concise steps involving 
“hot” chemicals has been developed (Fig. 9). The developed synthetic scheme included the sequential introduc-
tion of protecting groups to achieve the desired regioselectivity (Fig. 9). 5-Benzyloxyindole-3-carboxaldehyde 
Figure 7. Structure and pharmacological profile of tryptamine analogues.
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was subjected to the MCR protocol to yield 1y. This compound was N-Boc substituted to protect the indole NH 
group from alkylation during one of the last steps. The derivative was reductively debenzylated yielding tert-butyl 
3-(1-ethyl-1H-imidazol-5-yl)-5-hydroxy-1H-indole-1-carboxylate, ready for alkylation with 11CH3I. After alkyl-
ation with a non-radioactive CH3I, Boc group was easily cleaved using either hydrochloric or trifluoroacetic acid. 
A similar strategy, involving synthesis of a N-Boc protected indole derivative, ready for the introduction of an 
isotopically labelled alkyl fragment to the 1-position of imidazole, may be employed for the synthesis of 1o, or 
other 5-HT7R agonists.
Conclusions
To date there have been no examples of low-basicity agonists of serotonin receptors. We report a series of highly 
drug-like, low-basicity 5-HT7R agonists synthesized using MCR imidazole synthesis. The procedure described 
by van Leusen proceeded under various conditions: a range of solvents and bases are tolerable. Notably, the scope 
of the carbonyl and amine reagents is very broad. Hydroxy-, amino-, amido-, ester and other reactive groups do 
not interfere with the reaction.
There are several highly active, selective 5-HT7R ligands within the presented series. Hit compound 1o 
exhibits high affinity towards the receptor (Ki = 6 nM), intrinsic activity (EC50 = 19 nM), low intrinsic clearance 
(Clint = 6.3 ml/min/kg, human liver microsomes) and high predicted drug-likeness. These facts combined with an 
exceptional ease of synthesis may contribute to the use of radiolabeled 1o and 1e as potential molecular probes. 1e 
has 5-HT1A/5-HT7 receptor selectivity comparable to known 5-HT7R agonists, whereas 1o is 176-fold selective. 
Both compounds are very selective towards 5-HT5A which is not a common feature of 5-HT7R agonists. The com-
pounds are metabolically stable in human liver microsomes, exhibit very low toxicity in HEK-293 and HepG2 
cells and are water soluble. The blood-brain barrier permeation of 1o was found very high, which is consistent 
Figure 8. Representative complexes of selected tryptamines with 5-HT7 receptor. Amino acids that were 
selected as crucial for the binding of the presented compounds are shown as sticks. (A) – the superposition 
of tryptamine (cyan) and 1-methyltryptamine (orange). (B) – the halogen bond formed between Ser5.42 
and 5-chlorotryptamine (yellow). (C) – the superposition of 5-methoxytryptamine (green) and 1-methyl-
5-methoxytryptamine (magenta). (D) – a comparison of the binding modes of 1f (violet) and the analogous 
5-methoxytryptamine.
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with its high activity in vivo, where all three tested i.p. doses (0.5, 1 and 5 mg/kg) reversed MK-801 induced novel 
object recognition impairment in mice.
The proposed binding mode was developed by SAR analysis and homology modelling and involves the for-
mation of a hydrogen bond between the indole NH group and Asp3.32. The imidazole fragment is proposed to 
interact with Arg6.58 which could explain the unusually high selectivity that is not observed in tryptamines. The 
similar 5-HT7R SAR patterns of tryptamines and the described compounds can be attributed to the interaction 
of the substituents of indole at the 5th position with Ser5.42 leading to comparable binding affinity gains for the 
same substituents in the two series.
Structures of NCE’s in the area of medicinal chemistry have become increasingly complex due to the wide-
spread application of the hit-to-lead strategy and the rising palette of structural modifications that enable ADME 
optimization. We suppose that a better strategy for radioligand searches may be to find simple scaffolds exhibiting 
moderate to high activity that upon decoration with substituents would retain or improve their affinity for a given 
target, rather then finding sophisticated structures via virtual or high-throughput screening that upon simplifi-
cation may not yield any active scaffolds. Because the available chemical space of compounds with low molecular 
mass (MW < 250 Da) that pass drug likeness filters can be considered inexhaustible taking current synthetic 
methods into account, we suppose that there are still numerous privileged structures to be discovered. Quoting 
Richard Feynman: “There’s plenty of room at the bottom”.
Methods
Chemicals. All organic reagents were purchased from Sigma-Aldrich, Apollo Scientific Apollo Scientific 
Ltd, or Combi-Blocks and were used without purification. Solvents and inorganic reagents were acquired from 
Chempur. Reaction progress was monitored by TLC on Merck Silica Gel 60 F 254 on aluminium plates. Column 
chromatography was performed on Merck Silica Gel 60 (0.063–0.200 mm; 70–230 mesh ASTM).
Analytical Methods. UPLC/MS analysis was performed on Waters TQD spectrometer combined with 
UPLC Acquity H-Class with PDA eLambda detector. Waters Acquity UPLC BEH C18 1.7 μm 2.1 × 100 mm chro-
matographic column was used, at 40 °C, 0.300 ml/min flow rate and 1.0 μL injection volume (the samples were 
dissolved in LC-MS grade acetonitrile, typically at a concentration of 0.1–1 mg/ml prior to injection). All mass 
spectra were recorded under electrospray ionization in positive mode (ESI+) and chromatograms were recorded 
with UV detection in the range of 190–300 nm. The gradient conditions used were: 80% phase A (water+ 0.1% 
formic acid) and 20% phase B (acetonitrile + 0.1% formic acid) to 100% phase B (acetonitrile + 0.1% formic acid) 
at 3.0 minutes, kept till 3.5 minutes, then to initial conditions until 4.0 minutes and kept for additional 2.0 minutes. 
Total time of analysis – 6.0 minutes.
1H and 13C NMR spectra were recorded on a Bruker Avance III HD 400 NMR spectrometer. All samples were 
dissolved in DMSO-d6 with TMS as the internal standard. The spectral data of the compounds refer to their free 
bases.
All presented compounds were of at least 95% purity as determined by LC-MS. Syntheses and characterization 
details for intermediate products and final compounds as well as the spectral data for all compounds is included 
in the Supporting Information.
In vivo experiments. The pharmacokinetic experimental procedures were carried out in accordance with 
EU Directive 2010/63/EU and approved by the I Local Ethics Committee for Experiments on Animals of the 
Jagiellonian University in Krakow, Poland (approval number: 123/2015). The behavioural experiments were carried 
out in accordance with EU Directive 2010/63/EU and approved by the Local Ethics Committee for Experiments on 
Animals of the Institute of Pharmacology, Polish Academy of Sciences (approval number: 181/2016).
General Procedure 1 for the Synthesis of Compounds 1a–1q, 1s–1 v, 1y–1za, 2b–2f, and 
3a–3d. Aromatic aldehyde (3 mmol) was mixed with amine (15 mmol) in 20 ml dry methanol. Reaction 
Figure 9. Proposed synthetic scheme for the synthesis of radiolabeled 1e. Conditions: (a) – EtNH2, TosMIC, 
K2CO3, MeOH (85% - yield); (b) – Boc2O, DMAP, THF (85% yield); (c) – Pd/C, H2, MeOH (36% yield); (d) – 
11CH3I, NaOH, toluene, H2O, TBAB (25% yield); (e) – HCl, MeOH (97% yield).
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mixture was left overnight to complete the imine formation although it can be TLC monitored (SiO2/CHCl3). 
Anhydrous K2CO3 (3 mmol) and TosMIC (tosylmethylisocyanide, 3 mmol) were subsequently added. The mix-
ture was stirred for an additional 8 hours, diluted with 50 ml H2O, and extracted three times with 20 ml ethyl 
acetate. The combined extracts were washed twice with 20 ml H2O, and once with 20 ml brine, treated with 
anhydrous magnesium sulfate and evaporated. The final products were purified either by trituration under a 2:1 
hexane:isopropanol mixture, or chromatography on a short silicagel bed. The unreacted aldehydes were eluted 
with ethyl acetate or chloroform, and then a mixture of AcOEt:MeOH or CHCl3:MeOH was applied to elute the 
product.
General Procedure 2 for the Synthesis of Substituted Indole-3-carboxaldehydes. The 
Vilsmeier-Haack reagent was generated by the addition of 2 ml of POCl3 over the course of 15 minutes to 8 ml of 
dry DMF cooled in an ice-salt bath. After the addition was complete, the ice bath was removed and the contents 
of the flask were left to warm to room temperature over approx. 30 minutes. The substituted indole (21.9 mmol) 
was dissolved in 10 ml of DMF and added over a period of 15 minutes to the formylating mixture. The stirring was 
continued for an hour during which the flask contents were heated to 40 °C in a hot water bath. A total of 20 ml of 
5 M NaOH was added, and the mixture was diluted with H2O, quickly brought to a boil and left to cool slowly. The 
crystals were removed by filtration, washed with cold water and vacuum dried. The products thus obtained were 
in most cases sufficiently pure for the subsequent reactions. And the impure aldehydes were recrystallized from 
ethanol-water mixtures. The yields varied from 48 to 90%.
General Procedure 3 for the Synthesis of Substituted 1-Alkylindole-3-carboxaldehydes. A 
total of 10 mmol of an appropriate indole-carboxaldehyde, 50 ml of toluene, 36 ml of 30% NaOH solution, 
1 mmol (322 mg) tetrabutylammonium bromide (TBAB) and 10.5 mmol alkyl iodide (0.66 ml of methyl iodide, 
for instance) were placed in a stoppered flask. The mixture was stirred until the substrate disappeared on TLC (on 
average 12 h). After completion of the reaction, the phases were separated, next the organic extract was washed 
with 30 ml of H2O followed by 30 ml of brine, and was dried over MgSO4, and the toluene was stripped off in a 
rotary evaporator. The crude product was triturated twice with 5 ml of hexane:isopropanol 2:1 mixture, and was 
vacuum filtered and dried. The yields varied from 85 to 97%.
Unsubsituted indole-3-carboxaldehyde was synthesized at full scale according to the OrgSyn procedure56.
General Procedure 4 for the Synthesis of 1r and 1x (Reductive Debenzylation). The benzyl pro-
tected compound was dissolved in methanol in a pressure reactor, and 10 mol% Pd/C was added. The reactor 
was sealed and pressurized to 7 bar with H2, and the completion of the reaction was monitored with LC-MS. The 
mixture was then filtered through Celite which was then washed with MeOH. The solvent was stripped off on a 
rotary evaporator and the resulting solid was triturated under a hexane:isoporopanol:acetone 3:1:1 mixture. The 
yields were not lower than 90%.
3-(1-Ethyl-1H-imidazol-5-yl)-1H-indole-5-carboxamide (1za). The compound was synthesized from 
1p, the nitrile group hydrolysis was accomplished according to a modified procedure outlined by Agarwal et al.57.
A suspension of 1p (3.4 mmol, 0.8 g) in 1 ml MeOH and 5 ml THF was stirred in an ice-salt bath for 15 minutes 
until 0 °C was reached. Hydrogen peroxide (30% solution, 5.4 ml) was added dropwise keeping the temperature 
below 10 °C. Stirring was continued for 15 minutes and sodium hydroxide (20% solution, 5.4 ml) was added drop-
wise keeping temperature below 10 °C. The mixture was allowed to warm to room temperature and stirred for 
24 hours. The product was extracted from the reaction mixture with chloroform and purified by trituration with 
acetone. Yield: 81 mg (9%).
Radiosynthesis of 1e. Tert-butyl 5-(benzyloxy)-3-(1-ethyl-1H-imidazol-5-yl)-1H-indole-1-carboxylate 
(4). To a round bottom flask there was added: THF (15 ml), 1y (410 mg, 1.29 mmol), di-tert-butyl dicarbonate 
(590 mg, 2.7 mmol, 2.1 eq) and a catalytic amount of DMAP. The mixture was stirred until disappearance of the 
substrate on TLC. H2O (20 ml) and ethyl acetate (20 ml) were added, the phases separated, the aquous phase 
extracted twice with 10 ml ethyl acetate. The organic phase was washed with brine, dried over MgSO4 and evap-
orated. Crude product was of >95% purity and was used in the next step without purification. Yield: 485 mg 
(85%). An analytical sample was obtained via column chromatography (SiO2, ethyl acetate:hexane 2:1, then ethyl 
acetate).
Tert-butyl 3-(1-ethyl-1H-imidazol-5-yl)-5-hydroxy-1H-indole-1-carboxylate (5). 4 (200 mg, 0.48 mmol) was dis-
solved in 50 ml MeOH in a glass reactor. 10% Pd/C (50 mg) was added and the reactor was pressurized to 7 bar 
with hydrogen. The mixture was stirred overnight, filtered through celite and the celite bed was washed thrice 
with 20 ml MeOH. The solvent was evaporated and the residue was subjected to column chromatography (SiO2, 
ethyl acetate). Yield: 57 mg (36%).
Tert-butyl 3-(1-ethyl-1H-imidazol-5-yl)-5-methoxy-1H-indole-1-carboxylate (6). To a round bottom flask there 
were added: 3 ml toluene, 5 (100 mg, 0.305 mmol), CH3I (20 μL, 0.32 mmol, 1.05 eq), TBAB (10 mg, 0.0305 mmol, 
0.1 eq.) and 1 ml 30% NaOH solution. The mixture was stirred and the progress of the reaction was TLC mon-
itored. The mixture was diluted with 10 ml H2O, extracted three times with 10 ml ethyl acetate, the combined 
organic phase was washed with 10 ml H2O, 10 ml brine, dried over MgSO4 and evaporated. The crude product was 
purified via column chromatography (SiO2, ethyl acetate). Yield: 26 mg (25%).
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3-(1-Ethyl-1H-imidazol-5-yl)-5-methoxy-1H-indole hydrochloride (1e). 6 (10 mg, 0.0293 mmol) was suspended 
in 2 ml MeOH and one drop of concentrated hydrochloric acid was added. The mixture was refluxed for 3 h, and 
the solvent was evaporated. Yield: 7.9 mg (97%).
In Vitro Pharmacology. Cell Culture. HEK293 cells with stable expression of human serotonin 5-HT1AR, 
5-HT6 and 5-HT7bR or dopamine D2LR (obtained using of Lipofectamine 2000, Invitrogen) or CHO-K1 cells with 
plasmid containing the sequence coding for the human serotonin 5-HT2A receptor (Perkin Elmer) were main-
tained at 37 °C in a humidified atmosphere with 5% CO2 and were grown in Dulbecco’s Modified Eagle’s Medium 
containing 10% dialyzed fetal bovine serum and 500 μg/ml G418 sulfate. For membranes preparations, cells were 
subcultured into 150 cm2 cell culture flasks, grown to 90% confluence, washed twice with phosphate buffered 
saline (PBS) prewarmed to 37 °C, pelleted by centrifugation (200 g) in PBS containing 0.1 mM EDTA and 1 mM 
dithiothreitol, and stored at −80 °C57–59.
5-HT1A/5-HT2A/5-HT6/5-HT7/D2 Radioligand Binding Assays. The membrane preparation and gen-
eral assay procedures for the cloned receptors were adjusted to 96-microwell format as described in our former 
papers58–61. The cell pellets were thawed and homogenized in 10 volumes of assay buffer using an Ultra Turrax 
tissue homogenizer and were centrifuged twice at 35,000 g for 15 min at 4 °C, with incubation for 15 min at 37 °C 
in between the rounds of centrifugation. The composition of the assay buffers was as follows: for 5-HT1AR: 50 mM 
Tris–HCl, 0.1 mM EDTA, 4 mM MgCl2, 10 μM pargyline and 0.1% ascorbate; for 5-HT2AR: 50 mM Tris–HCl, 
0.1 mM EDTA, 4 mM MgCl2 and 0.1% ascorbate; for 5-HT6R: 50 mM Tris–HCl, 0.5 mM EDTA and 4 mM MgCl2, 
and for 5-HT7bR: 50 mM Tris–HCl, 4 mM MgCl2, 10 μM pargyline and 0.1% ascorbate; for dopamine D2LR: 
50 mM Tris–HCl, 1 mM EDTA, 4 mM MgCl2, 120 mM NaCl, 5 mM KCl, 1.5 mM CaCl2 and 0.1% ascorbate.
All assays were incubated in a total volume of 200 μL in 96-well microtiter plates for 1 h at 37 °C, except for 
5-HT1AR and 5-HT2AR, which were incubated at room temperature and 27 °C, respectively. The equilibration pro-
cess was terminated by rapid filtration through Unifilter plates with a 96-well cell harvester and the radioactivity 
retained on the filters was quantified using a Microbeta plate reader (PerkinElmer, USA).
For the displacement studies, the assay samples contained the following as radioligands (PerkinElmer, USA): 
1.5 nM [3H]-8-OH-DPAT (135.2 Ci/mmol) for 5-HT1AR; 2 nM [3H]-ketanserin (53.4 Ci/mmol) for 5-HT2AR; 
2 nM [3H]-LSD (83.6 Ci/mmol) for 5-HT6R, 0.6 nM [3H]-5-CT (39.2 Ci/mmol) for 5-HT7R or [3H]-Raclopride 
(74.4 Ci/mmol). Non-specific binding was defined using 10 μM of 5-HT in 5-HT1AR and 5-HT7R binding experi-
ments, whereas 20 µM of mianserin, 10 μM of methiothepine or 1 μM of (+) butaclamol was used in the 5-HT2AR, 
5-HT6R and D2LR assays, respectively. Each compound was tested in triplicate at 7–8 concentrations (10–11–
10–4 M). The inhibition constants (Ki) were calculated using the Cheng-Prusoff equation62 and the results were 
expressed as the means of at least two independent experiments.
Functional Assay. The functional properties of compounds in HEK293 cells overexpressing 5-HT7R were 
evaluated for their ability to increase cAMP production for the agonists or to inhibit 10 nM 5-CT at a concentra-
tion producing 90% (EC90) of the maximum agonist activation for the antagonists.
Each compound was tested at 8 concentrations in the range of 10−11–10−4 M. Cells (prepared with the use of 
Lipofectamine 2000) were maintained at 37 °C in a humidified atmosphere with 5% CO2 and were grown in DMEM 
containing 10% dialyzed (FBA) and 500 µg/ml G418 sulfate. For the functional experiments, the cells were subcul-
tured in 25 cm2 diameter dishes, grown to 90% confluence, washed twice with PBS prewarmed to 37 °C and centri-
fuged for 5 min (160 × g). The supernatant was aspirated, and the cell pellet was resuspended in stimulation buffer 
(1 × HBSS, 5 mM HEPES, 0.5 mM IBMX, and 0.1% BSA). The total cAMP was measured using the LANCE cAMP 
detection kit (PerkinElmer), according to the manufacture’s directions. For the cAMP level quantification, cells (5 µl) 
were incubated with compounds (5 µl) for 30 min at room temperature in a 384-well white opaque microtiter plate. 
After incubation, 10 µl working solution (5 µl Eu-cAMP and 5 µl ULight-anti-cAMP) was added to stop the reaction 
and induced cells lysis. The assay plate was incubated for 1 h at room temperature and time-resolved fluorescence 
resonance energy transfer (TR-FRET) was detected by an Infinite M1000 Pro (Tecan, Männedorf, Switzerland) using 
instrument settings from the LANCE cAMP detection kit manual.
Molecular Modeling. Homology Modeling. Homology models of the 5-HT7 receptor were built on a 
GPCR crystal structures co-crystalized with agonist molecules, i.e. 5-HT1B (PDB ID: 4IAR, 4IAQ), 5-HT2B (PDB 
ID: 4IB4), A2A (PDB ID: 3QAK, 2YDV, 4UHR), β2 (PDB ID: 3P0G, 4LDE, 3PDS) and M2 (PDB ID: 4MQS) 
receptors, retrieved from the Protein Data Bank63. Sequences of the modeled receptor and selected templates 
were aligned manually using Accelrys Discovery Studio64, making sure that the most conserved amino acid in 
each helix, and the motif characteristic for class A GPCRs were in equivalent positions. The ranges of helices 
were determined on the basis of the crystal structures, and the loop regions were modeled, but not refined. For 
each template, 20 models were generated using Modeller software65, and were tested by the docking of active 
and inactive compounds, and enrichment calculation. For every model, ROC curves were calculated based on 
the Glide Score values of the docked compounds (the undocked actives and inactives were considered as false 
negatives and true negatives, respectively). The quality of the models was determined by the Area Under the ROC 
curve (AUROC). Three models per template with the highest AUROC value were selected for further studies. The 
final validation of the selected receptor models was performed by using the QM/MM molecular docking (QPLD 
Protocol) of the whole set of studied molecules. The models for which binding modes coherent for the whole set 
of compounds and explaining the main structure-activity relationships were observed were kept.
CNS MPO Calculation. The Central Nervous System Multiparameter Optimization (CNS MPO) scores 
were calculated based on the six basic physicochemical molecular descriptors: logP, logD, molecular weight 
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(MW), topological polar surface area (TPSA), the count of hydrogen bond donor (HBD), and the strongest basic 
pKa. All descriptors were calculated using Chemaxon’s Calculator Plugins66. A monotonically decreasing func-
tion was used to transform the values of the descriptors into dimensionless scale logP, logD, MW, HBD, and pKa 
whereas a hump function was used to transform TPSA. The most desirable and least desirable ranges for each 
physicochemical descriptor were adopted from the original paper50. Transformed values (desirability score) of the 
six descriptors were determined and summed up for each compound, to obtain the final CNS MPO, which can 
range from 0 (the worst CNS drug) to 6 (best CNS drug).
QM/MM Docking Protocol. The Quantum Mechanics/Molecular Mechanics (QM/MM) docking of all syn-
thesized compounds to 5-HT7R homology models were performed by means of the QM-Polarized Ligand Docking 
Protocol (QPLD)67 from Schrödinger Suite. At the first stage of the QPLD procedure the ligands were initially 
docked into a rigid protein using Glide. The resulting binding modes of the ligands were then used for the calcula-
tion of the partial charges of the ligand by a single-point calculation in QSite treating the ligand with the ab initio 
(B3PW91/cc-pVTZ) and the receptor with MM (OPLS-2005) level of theory. The partial atomic charges of the 
ligand molecules were recalculated using the electrostatic potential fitting method under the influence of external 
fields exerted by the surrounding protein atoms within and near the binding site. At the final stage, Glide re-docked 
the ligands using new charges, and the 10 most energetically favorable poses were returned for each ligand.
Binding Free Energy Calculation. MM-GBSA (Generalized-Born/Surface Area) was used to calculate the 
binding free energy for all ligand-receptor complexes to select the correct poses between possible binding modes. 
The binding free energy was calculated using ligand charges obtained via the QM/MM calculations using Prime 
software from Schrodinger. To assess the influence of a given substituent on the binding, the ΔΔG was calculated 
as a difference between binding free energy (ΔG) of unsubstituted (1w) and substituted analogues.
Plotting Interaction Spheres for Halogen Bonding. To visualize (plotting interaction spheres) the 
possible contribution of halogen bonding for the resulting ligand-receptor complexes, the halogen bonding web-
server was used (access 1.4.2016, http://www.halogenbonding.com/).
Associated Content. Syntheses and characterization details for intermediate products and final compounds, 
cell culture and transfection methods, pharmacological data for compound 2a, detailed description of: metabolic 
stability assays for compound 1e and 1o, cytotoxicity assays, metabolic stability assays, pharmacokinetic study, 
novel object recognition experiment, 1H NMR, 13C NMR and LC-MS spectra (PDF).
Molecular formula strings (CSV).
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